The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients

NCT05527444 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Ankylosing Spondylitis

Interventions

DRUG: Secukinumab 150 mg/ml
DRUG: Adalimumab Ab
DRUG: NSAID
DRUG: Thalidomide Pill

Sponsor

Qilu Hospital of Shandong University